Advertisement

Clinical and Translational Oncology

, Volume 18, Issue 8, pp 769–775 | Cite as

Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)

  • E. GrandeEmail author
  • J. Santamaría Sandi
  • J. Capdevila
  • E. Navarro González
  • C. Zafón Llopis
  • T. Ramón y Cajal Asensio
  • J. M. Gómez Sáez
  • P. Jiménez-Fonseca
  • G. Riesco-Eizaguirre
  • J. C. Galofré
Review Article

Abstract

Background

Of all thyroid cancers, <5 % are medullary (MTC). It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny.

Methods

The electronic search was conducted using MEDLINE (PubMed), EMBASE and Cochrane Central Register of Controlled Trials. Quality assessments of selected current articles, guidelines and reviews of MTC were performed.

Results

This consensus updates and summarizes biology, treatment and prognostic considerations of MTC.

Conclusions

Multidisciplinary teams and specialized centers are recommended for the management of MTC patients. In the metastatic setting, those patients with large volume of disease are candidates to start systemic treatment mainly if they are symptomatic and the tumor has progressed in the last 12–14 months. Wait and see strategy should be offered to patients with: disseminated disease with only high levels of calcitonin and no macroscopic structural disease, low burden and absence of progression.

Keywords

Cabozantinib Calcitonin Carcinoembryonic antigen Medullary thyroid carcinoma Thyroid cancer Review Vandetanib 

References

  1. 1.
    Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am. 2014;43:423–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 2011;21:125–34.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Valle LA, Kloss RT. The prevalence of occult medullary thryroid carcinoma at autopsy. J Clin Endocrinol Metab. 2011;96:E109–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292–306.CrossRefPubMedGoogle Scholar
  5. 5.
    Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Jimenez C, Hu MI, Gagel RF. Management of thyroid carcinoma. Endocrinol Metab Clin North Am. 2008;37:481–96.CrossRefPubMedGoogle Scholar
  7. 7.
    Reynolds L, Jones K, Winton DJ, Cranston A, Houghton C, Howard L, et al. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Oncogene. 2001;20:3986–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010;16:5936–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Valdes N, Navarro E, Mesa J, Casteras A, Alcazar V, Lamas C, et al. RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. Eur J Endocrinol. 2015;172(3):301–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol. 2000;11:19–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Chernock RD, Hagemann IS. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas. Am J Clin Pathol. 2015;143(6):768–77.CrossRefPubMedGoogle Scholar
  13. 13.
    Moura MM, Cavaco BM, Leite V. RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer. 2015;22(5):R235–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Hodack SP, Burman KD. The calcitonin conundrum—is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab. 2004;89:511–4.CrossRefGoogle Scholar
  16. 16.
    Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029–34.CrossRefPubMedGoogle Scholar
  17. 17.
    Giraudet LA, Ghulzan AA, Aupérin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239–46.CrossRefGoogle Scholar
  18. 18.
    Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Skoura E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11(4):e8156.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40(6):943–66.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW, et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1:5–14.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Callender GG, Carling T, Christison-Lagay E, Udelsman R. Surgery for thyroid cancer. Endocrinol Metab Clin North Am. 2014;43:443–58.CrossRefPubMedGoogle Scholar
  23. 23.
    Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645–55.PubMedGoogle Scholar
  24. 24.
    Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284–90.PubMedGoogle Scholar
  25. 25.
    Herbst RS, Heymach JV, O’Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs. 2007;16:239–49.CrossRefPubMedGoogle Scholar
  26. 26.
    Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Clin Oncol J. 2012;30:134–41.CrossRefGoogle Scholar
  27. 27.
    Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Dev Ther. 2015;9:3459–70.Google Scholar
  28. 28.
    Karras S, Pontikides N, Krassas GE. Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer. Expert Opin Drug Metab Toxicol. 2013;9:507–15.CrossRefPubMedGoogle Scholar
  29. 29.
    Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639–46.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Call JA, Caudill JS, McIver B, Foote RL. A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience. Rare Tumors. 2013;12(5):e37.CrossRefGoogle Scholar
  31. 31.
    Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88:2070–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Fromigué J, de Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2496–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des Tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998;48:265–73.CrossRefGoogle Scholar
  34. 34.
    Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134–42.CrossRefPubMedGoogle Scholar
  35. 35.
    Pazaitou-Panayiotou K, Chrisoulidou A, Mandanas S, Tziomalos K, Doumala E, Patakiouta F. Predictive factors that influence the course of medullary thyroid carcinoma. Int J Clin Oncol. 2014;19(3):445–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Díez JJ, Galofré JC, Oleaga A, Grande E, Mitjavila M, Moreno P. en representación del Grupo de Trabajo de Cáncer de Tiroides de la Sociedad Española de Endocrinología y Nutrición. Consensus statement for accreditation of multidisciplinary thyroid cancer units. Endocrinol Nutr. 2015. doi: 10.1016/j.endonu.2015.07.005.Google Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  • E. Grande
    • 1
    Email author
  • J. Santamaría Sandi
    • 2
  • J. Capdevila
    • 3
  • E. Navarro González
    • 4
  • C. Zafón Llopis
    • 5
  • T. Ramón y Cajal Asensio
    • 6
  • J. M. Gómez Sáez
    • 7
  • P. Jiménez-Fonseca
    • 8
  • G. Riesco-Eizaguirre
    • 9
  • J. C. Galofré
    • 10
  1. 1.Servicio de Oncología MédicaHospital Ramón y CajalMadridSpain
  2. 2.Endocrinology and Nutrition ServiceHospital Universitario de CrucesVizcayaSpain
  3. 3.Medical Oncology ServiceHospital Universitario Vall d’HebronBarcelonaSpain
  4. 4.Endocrinology and Nutrition ServiceHospital Universitario Virgen del RocioSevilleSpain
  5. 5.Endocrinology and Nutrition ServiceHospital Universitario Vall d’HebronBarcelonaSpain
  6. 6.Medical Oncology ServiceHospital de la Santa Creu i Sant PauBarcelonaSpain
  7. 7.CIBERDEM, Endocrinology and Nutrition ServiceHospital Universitario de BellvitgeBarcelonaSpain
  8. 8.Medical Oncology ServiceHospital Universitario Central de AsturiasOviedoSpain
  9. 9.Endocrinology and Nutrition ServiceHospital Universitario de MóstolesMadridSpain
  10. 10.Endocrinology and Nutrition ServiceClínica Universidad de NavarraPamplonaSpain

Personalised recommendations